21-Mar-2006 - Merck & Co., Inc.

Neuromed Pharmaceuticals and Merck & Co., Inc. Announce Agreement for Novel N-type Calcium Channel Compounds

Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced that they have signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound, NMED-160, which is currently in Phase II development for the treatment of pain.

Under the terms of the agreement, Neuromed grants Merck an exclusive worldwide license to research, develop and commercialize NMED-160 and other compounds that selectively target the N-type calcium channel. Merck will make a $25 million initial cash payment to Neuromed. Neuromed will also receive research funding from Merck for two years as part of the collaborative research program, including the option to renew for an additional two years. Merck is responsible for all development costs and activities.

The successful development and launch of NMED-160 for an initial single indication on a worldwide basis would trigger milestone payments totaling $202 million. Milestones could increase to approximately $450 million if a further indication for NMED-160 is developed and approved and a further compound is developed and approved for two indications. Neuromed would also receive royalties on worldwide sales of NMED-160 and any additional compounds developed under this agreement. Additional milestone payments would be payable should further compounds be developed. Further financial terms were not disclosed.

Facts, background information, dossiers
  • Merck
  • Neuromed Pharmaceuticals
  • milestone payments
  • neurological disorders
  • milestones
  • license agreements
More about Merck Sharp & Dohme
  • News

    Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates

    Merck, known as MSD outside the United States and Canada, announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeut ... more

    Seattle Genetics and Merck & Co Announce Two Strategic Oncology Collaborations

    Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations. The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting ... more

    Vienna vaccine start-up to be acquired by MSD

    Themis and MSD (trademark of Merck & Co., Inc.) announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis.  Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using ... more

  • Companies

    Merck Sharp & Dohme Limited

    We are inspired by the difference we can make in the lives of people around the world through the innovative medicines, vaccines, and consumer health and animal products we discover and produce. Our products cover a broad range of areas, including heart and respiratory health, infectious di ... more

More about Neuromed Pharmaceuticals